dc.contributor.author | Turkes, F | |
dc.contributor.author | Carmichael, J | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Starling, N | |
dc.coverage.spatial | Egypt | |
dc.date.accessioned | 2022-09-02T08:44:23Z | |
dc.date.available | 2022-09-02T08:44:23Z | |
dc.date.issued | 2019-12-18 | |
dc.identifier | ARTN 7698786 | |
dc.identifier.citation | Gastroenterology Research and Practice, 2019, 2019 pp. 7698786 - | |
dc.identifier.issn | 1687-6121 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5375 | |
dc.identifier.eissn | 1687-630X | |
dc.identifier.eissn | 1687-630X | |
dc.identifier.doi | 10.1155/2019/7698786 | |
dc.description.abstract | Biliary tract cancers (BTCs) are poor prognosis malignancies with limited treatment options. Capecitabine has recently emerged as an effective agent in the adjuvant setting; however, treatment of advanced disease is still limited to first-line cisplatin and gemcitabine chemotherapy. Recent global efforts in genomic profiling and molecular subtyping of BTCs have uncovered a wealth of genomic aberrations which may carry prognostic significance and/or predict response to treatment, and several targeted agents have shown promising results in clinical trials. As such, the uptake of comprehensive genomic profiling for patients with BTCs and the expansion of basket trials to include these patients are growing. This review describes the currently approved systemic therapies for BTCs and provides insight into the emerging targeted and immunotherapeutic agents, as well as conventional chemotherapeutic regimes, currently being investigated in clinical trials. | |
dc.format | Electronic-eCollection | |
dc.format.extent | 7698786 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | HINDAWI LTD | |
dc.relation.ispartof | Gastroenterology Research and Practice | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Science & Technology | |
dc.subject | Life Sciences & Biomedicine | |
dc.subject | Gastroenterology & Hepatology | |
dc.subject | PHASE-II TRIAL | |
dc.subject | OPEN-LABEL | |
dc.subject | GEMCITABINE CHEMOTHERAPY | |
dc.subject | GROWTH-FACTOR | |
dc.subject | OXALIPLATIN | |
dc.subject | CISPLATIN | |
dc.subject | CHOLANGIOCARCINOMA | |
dc.subject | COMBINATION | |
dc.subject | GALLBLADDER | |
dc.subject | MULTICENTER | |
dc.title | Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-09-05 | |
dc.date.updated | 2022-09-02T08:43:39Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1155/2019/7698786 | |
rioxxterms.licenseref.startdate | 2019-12-18 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/31929787 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.) | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/20/21 Starting Cohort | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1155/2019/7698786 | |
pubs.volume | 2019 | |
icr.researchteam | PrCa Targeted Therapy | |
icr.researchteam | Medicine (RMH) | |
dc.contributor.icrauthor | Carmichael, Juliet | |
icr.provenance | Deposited by Mr Arek Surman on 2022-09-02. Deposit type is initial. No. of files: 1. Files: Contemporary Tailored Oncology Treatment of Biliary Tract Cancers.pdf | |